David Hung | BiotechTV

top of page

Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio

He discusses the clinical profile of IBTROZI, how the launch is going, and describes other work the company is doing in precision...

Company News

Oct 8

Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June

He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates,...

Company News

Apr 9

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio

Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June

Follow BiotechTV

Sponsors

Sponsor Spotlight